Allergan Announces Collaboration with AstraZeneca to Develop and Commercialize ATM-AVI for Antibiotic-Resistant Gram-Negative Infections


Allergan has entered into a global agreement with AstraZeneca to develop and commercialize ATM-AVI, an investigational, fixed-dose antibiotic combining aztreonam and avibactam.




Jan. 29, 2016

/PRNewswire/ --

Allergan plc

(NYSE: AGN) today announced that it has entered into a global agreement with


to develop and commercialize ATM-AVI, an investigational, fixed-dose antibiotic combining aztreonam and avibactam. Together, the two companies will evaluate the combination to treat serious infections caused by metallo βlactamase MBL-producing Gram-negative pathogens, a difficult-to-treat sub-type of carbapenem-resistant Enterobacteriaceae (CRE), for which there are currently very limited treatments, thus presenting a new treatment option for patients with MBL-producing pathogens. Under the terms of the agreement,


will maintain commercialization rights in the U.S. and




will maintain commercialization rights in all other countries.

ATM-AVI is the first drug candidate to be developed under a public-private partnership agreement between


and the

Biomedical Advanced Research and Development Authority



), a part of the

U.S. Department of Health


Human Services' Office of the Assistant Secretary for Preparedness and Response



). Announced in

September 2015

, the goal of this strategic alliance is to develop a portfolio of drug candidates over the next five years with dual uses in treating illnesses caused by bioterrorism agents and antibiotic-resistant infections.

"The rate of antibiotic resistance continues to increase worldwide, representing a truly global threat that requires collaboration and sustained commitment from industry and government to develop solutions," said

David Nicholson

, Executive Vice President,

Global Brands Research

and Development,


. "As a leader in anti-infectives, we are dedicated to the ongoing research and development of innovative products, like ATM-AVI, for patients with difficult-to-treat infections who, today, have very few or no effective options."

Aztreonam is not inactivated by MBLs, as a single agent it has limited utility because the vast majority of MBL-producing pathogens also express serine-β-lactamases that can inactivate it. With avibactam's ability to inhibit many serine-β-lactamase enzymes, aztreonam's activity is restored against pathogens that co-produce MBLs and serine enzymes, thus presenting a new treatment option for patients.

"This collaboration represents an important milestone in the development of ATM-AVI. Antimicrobial resistance is a huge global health challenge, which is increasingly at the forefront of the public health agenda. We look forward to working with health authorities to help bring this much-needed new treatment option to patients," said Hans Sijbesma, Managing Director, Antibiotics Business Unit, AstraZeneca.

The European Union's

Innovative Medicines Initiative (IMI), a partnership between the

European Union

and the European pharmaceutical industry, is currently supporting the Phase 2 clinical study of ATM-AVI in


under a project called COMBACTE-CARE and is joining. BARDA and


in supporting global phase 3 clinical development needed to apply for regulatory approval of ATM-AVI.

Related Videos
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg -
Image credit: |
Medical team -- Image credit: Flamingo Images |
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin -
© 2024 MJH Life Sciences

All rights reserved.